window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 2, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    AI-powered bioreactor project aims to transform biologics manufacturing

    A Canada–UK collaboration is developing an AI-driven bioreactor platform designed [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Kling Bio and Sanofi collaborate to accelerate discovery of next-generation antiviral antibodies

    Biotech company Kling Bio has announced a new collaboration with [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    Why immunotherapy sometimes fails: Study reveals unintended effects of antibody design

    A new study from researchers in Japan has uncovered a [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation,Manufacturing & Supply Chain

    Stevanato Group secures €200 million to support global capacity expansion for drug delivery solutions

    Stevanato Group has secured €200 million in financing to support [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    Solvias expands US cGMP testing capabilities with RTP center phase 2 build-out

    Solvias has achieved Current Good Manufacturing Practice (cGMP) readiness at [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    Lonza upgrades CDMO outlook following strong H1 2025 performance

    Lonza has raised its full-year 2025 guidance for its contract [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    MSD strengthens commercial capabilities with commitment to Veeva Vault CRM ahead of major launches

    Global pharma leader MSD (Merck outside the US and Canada) [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    PhoreMost unveils breakthrough platform to rationalise molecular glue drug discovery

    High-throughput GlueSEEKER platform expands druggable space by identifying novel induced [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Opinion & Events,Therapeutic Areas

    New research partnership targets $1 malaria prevention shot using next-gen biologics

    Eyam Health, a Canadian biotech, teams with Medicines for Malaria [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Neuraxpharm expands global reach with launch of Australian affiliate

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on [...]

    May 5, 2026
Previous192021Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Faeth Therapeutics focuses on PIKTOR as oncology Phase 2 data nears
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • ZoBio launches DNA-encoded library hit discovery service for difficult drug targets
    Categories: Biotech & Pharma Business, Drug Discovery & Development
  • Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top